Effectiveness of 1st-line treatment options in mRCC – a German RCC-Registry evaluation.

Goebell, P.J., Müller, L., Lück, A., Overkamp, F., Vogt, M., Marschner, N., 2014.

J Clin Oncol, ASCO GU, San Francisco 32, (suppl.4; abstr 429). doi:10.1200/jco.2014.32.4_suppl.429

Studie: TNK; Indikation: Nierenzellkarzinom; Jahr: 2014; Veranstaltung: GCS (ASCO); Journal: Journal of Clinical Oncology

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com